Volume 4, Issue 2

Cholinesterase: Not a robust marker of systemic low-grade inflammation in hypertension

Author

Amisha Suri1, Navjot Singh Samplay1, Rajinder Singh1, Sudhir Varma2, Harcharan Singh3and Kanchan Vohra4*

Abstract

A prospective case-control study evaluated the novel risk marker cholinesterase (ChE) in comparison to a well-known marker high sensitivity C reactive protein (hsCRP) to predict the presence of low grade systemic inflammation and to find its applicability for being used in place of hsCRP to predict the risk of CVD. Method: 285 healthy and 960 hypertensive subjects with/without coexisting cardiac/metabolic diseases were enrolled. Patients were categorized in to three categories: firstly, based on hsCRP levels (<1, 1-3, 3-10mg/l), secondly, based on number of coexisting diseases/risk factors (one, two, three), and thirdly, based on stage of hypertension (pre-, stage 1, stage 2 hypertension), each into three sub-groups, respectively. Results: Increased serum levels of both hsCRP (mg/l) and ChE (U/L) were found in all three groups and subgroups (based on: hsCRP, risk factors, hypertension stage) of patients (all p<0.05) as compared to healthy subjects. Although, ChE was significantly correlated with hsCRP in both healthy and patient groups (p<0.01), yet it was affected by more number of variables than hsCRP. Conclusion: ChE can act as a marker of low grade systemic inflammation but not as robust as hsCRP to predict the risk of CVD.

DOI

https://doi.org/10.62226/ijarst20150204

PAGES : 322-329 | 37 VIEWS | 92 DOWNLOADS

Download Full Article